Technetium Tc-99m pertechnetate API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Technetium Tc-99m pertechnetate API 23288-61-1?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Technetium Tc-99m pertechnetate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Technetium Tc-99m pertechnetate
- Synonyms:
- (99Tc)pertechnetate , CPERT , GPERT , Pertechnetate-99Tc , Technetium (99mTc) Pertechnetate , Technetium Tc 99m Pertechnetate
- Cas Number:
- 23288-61-1
- DrugBank number:
- DB09314
- Unique Ingredient Identifier:
- PPP8783IQ1
General Description:
Technetium Tc-99m pertechnetate, identified by CAS number 23288-61-1, is a notable compound with significant therapeutic applications. Technetium Tc-99m pertechnetate is a radiopharmaceutical diagnostic agent composed of an oxoanion with the chemical formula TcO4-. Pertechnetate has a wide variety of uses within nuclear medicine as it distributes within the body to a similar extent as iodine. It also concentrates in the thyroid gland, salivary glands, gastric mucosa, and choroid plexus. However, in contrast to the iodide ion, the pertechnetate ion is released unchanged from the thyroid gland. Currently marketed as the product Drytec, technetium-99m pertechnetate is indicated for imaging of the following tissues: thyroid, salivary gland, urinary bladder (for detection of vesico-ureteral reflux), and the nasolacrimal drainage system. Technetium-99m's short half life (6 hours) makes storage impossible, therefore it is supplied as its parent nuclide molybdenum-99, which spontaneously decays to technetium-99 through beta decay. This is normally supplied in a hospital setting through the use of a technetium-99m generator, whereby technetium exits the generator in the form of the pertechnetate ion, TcO4−, which can be extracted and promptly used for clinical diagnostics. Following intravenous injection, single photon emission computed tomography (SPECT) is performed to detect the gamma ray emmitted by the decay of Technetium-99m to Technetium-99.
Indications:
This drug is primarily indicated for: Sodium Pertechnetate Tc99m Injection is indicated for use in adults for imaging in the following tissues: thyroid, salivary gland, urinary bladder (for detection of vesico-ureteral reflux), and nasolacrimal drainage system (dacryoscintigraphy). It is indicated for use in children for imaging the following tissues: thyroid and urinary bladder. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Technetium Tc-99m pertechnetate functions by: The pertechnetate ion distributes in the body similarly to the iodide ion, but is not organified when trapped in the thyroid gland. It also concentrates in the thyroid gland, salivary glands, gastric mucosa, and choroid plexus. However, in contrast to the iodide ion, the pertechnetate ion is released unchanged from the thyroid gland. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Categories:
Technetium Tc-99m pertechnetate is categorized under the following therapeutic classes: Compounds used in a research, industrial, or household setting, Diagnostic Radiopharmaceuticals, Diagnostic Uses of Chemicals, Indicators and Reagents, Laboratory Chemicals, Radioactive Diagnostic Agent, Radiopharmaceutical Activity, Radiopharmaceuticals, Technetium Compounds, Thyroid Diagnostic Radiopharmaceuticals. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Technetium Tc-99m pertechnetate is a type of Diagnostic agents
Diagnostic agents are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) used in the field of medical diagnostics. These agents play a vital role in diagnosing various diseases and conditions by aiding in the visualization and identification of specific biomarkers or structures within the body.
Diagnostic agents encompass a wide range of substances, including contrast agents, radiopharmaceuticals, and imaging agents. Contrast agents are commonly used in medical imaging techniques such as X-rays, magnetic resonance imaging (MRI), and computed tomography (CT) scans. They enhance the visibility of certain tissues or organs, allowing healthcare professionals to detect abnormalities more accurately.
Radiopharmaceuticals are another type of diagnostic agent that combines a radioactive component with a pharmaceutical compound. These agents emit radiation that can be detected by specialized imaging equipment, enabling the visualization of metabolic processes and the identification of abnormal cellular activity.
Imaging agents are designed to target specific molecular structures or biomarkers within the body. They can be used to detect and visualize specific proteins, enzymes, or receptors associated with certain diseases or conditions. By targeting these specific biomarkers, imaging agents provide valuable information about the presence, location, and extent of a disease, aiding in diagnosis and treatment planning.
Overall, diagnostic agents are essential tools in modern medicine, facilitating accurate and timely diagnoses. These pharmaceutical APIs enable healthcare professionals to identify and monitor diseases at an early stage, leading to better patient outcomes and improved treatment strategies.
